M2e Nanoparticle Vaccines: Rational Design for Universal Influenza A

This narrative review synthesizes preclinical design principles for Matrix 2 ectodomain (M2e) universal influenza A vaccines, relevant to immunology pharmacists tracking next-generation, non-hemagglutinin vaccine platforms.

M2eMatrix 2 ectodomainuniversal influenza vaccineinfluenza Ananoparticle vaccineself-assembling protein nanoparticlevirus-like particleFc-mediated immunityADCCADCPnarrative reviewimmunology Rheumatology / Immunology

Background Information

M2e-based nanoparticles aim for universal influenza A protection.

Influenza A virus has significant health and economic impacts due to its antigenic variability, which current vaccines struggle to address. M2e-based vaccines target infected cells and offer potential universal protection, but require optimization of antigen presentation and use in multivalent nanoparticle platforms. While no M2e-based vaccine is licensed yet, this approach could offer broad, durable protection, advancing pandemic preparedness. M2e-based nanoparticles could revolutionize universal influenza A protection with further development.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Bourlon L, Morlieras J, Marche PN, Navarro FP

Citation: Bourlon L, Morlieras J, Marche PN, et al. Rational design of M2e-based nanoparticle vaccines for universal influenza a protection. Expert review of vaccines. 2026;25(1):2719046. doi:10.1080/14760584.2026.2719046

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →